Is TG Therapeutics, Inc. (TGTX) A Good Stock To Buy Now?
Key takeaways
- Ricardo Pillai Fri, June 19, 2026 at 11:22 PM GMT+7 3 min read TGTX Is TGTX a good stock to buy?
- The company’s lead therapy, BRIUMVI, is an anti-CD20 monoclonal antibody designed to selectively deplete immune cells that drive inflammatory damage in relapsing forms of MS.
- Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Is TG Therapeutics, Inc. (TGTX) A Good Stock To Buy Now? Ricardo Pillai Fri, June 19, 2026 at 11:22 PM GMT+7 3 min read TGTX Is TGTX a good stock to buy? We came across a bullish thesis on TG Therapeutics, Inc. on Traders Pro’s Substack. In this article, we will summarize the bulls’ thesis on TGTX. TG Therapeutics, Inc. s share was trading at $50.54 as of June 16th. TGTX’s trailing and forward P/E were 17.59 and 38.76 respectively according to Yahoo Finance.
TG Therapeutics, Inc. (TGTX) is a commercial-stage biopharmaceutical company focused on treating multiple sclerosis, positioned within profitable, revenue-generating specialty pharma businesses with durable commercial traction, supported by strong recurring revenue visibility. The company’s lead therapy, BRIUMVI, is an anti-CD20 monoclonal antibody designed to selectively deplete immune cells that drive inflammatory damage in relapsing forms of MS.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich